1.Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment
Hyo Seon RYU ; Hyun Jung KIM ; Woong Bae JI ; Byung Chang KIM ; Ji Hun KIM ; Sung Kyung MOON ; Sung Il KANG ; Han Deok KWAK ; Eun Sun KIM ; Chang Hyun KIM ; Tae Hyung KIM ; Gyoung Tae NOH ; Byung-Soo PARK ; Hyeung-Min PARK ; Jeong Mo BAE ; Jung Hoon BAE ; Ni Eun SEO ; Chang Hoon SONG ; Mi Sun AHN ; Jae Seon EO ; Young Chul YOON ; Joon-Kee YOON ; Kyung Ha LEE ; Kyung Hee LEE ; Kil-Yong LEE ; Myung Su LEE ; Sung Hak LEE ; Jong Min LEE ; Ji Eun LEE ; Han Hee LEE ; Myong Hoon IHN ; Je-Ho JANG ; Sun Kyung JEON ; Kum Ju CHAE ; Jin-Ho CHOI ; Dae Hee PYO ; Gi Won HA ; Kyung Su HAN ; Young Ki HONG ; Chang Won HONG ; Jung-Myun KWAK ;
Annals of Coloproctology 2024;40(2):89-113
Colorectal cancer is the third most common cancer in Korea and the third leading cause of death from cancer. Treatment outcomes for colon cancer are steadily improving due to national health screening programs with advances in diagnostic methods, surgical techniques, and therapeutic agents.. The Korea Colon Cancer Multidisciplinary (KCCM) Committee intends to provide professionals who treat colon cancer with the most up-to-date, evidence-based practice guidelines to improve outcomes and help them make decisions that reflect their patients’ values and preferences. These guidelines have been established by consensus reached by the KCCM Guideline Committee based on a systematic literature review and evidence synthesis and by considering the national health insurance system in real clinical practice settings. Each recommendation is presented with a recommendation strength and level of evidence based on the consensus of the committee.
2.2023 Korean Multidisciplinary Guidelines for Colon Cancer Management: Summary of Radiological Points
Nieun SEO ; Hyo Seon RYU ; Myungsu LEE ; Sun Kyung JEON ; Kum Ju CHAE ; Joon-Kee YOON ; Kyung Su HAN ; Ji Eun LEE ; Jae Seon EO ; Young Chul YOON ; Sung Kyung MOON ; Hyun Jung KIM ; Jung-Myun KWAK
Korean Journal of Radiology 2024;25(9):769-772
3.Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma
Kum Hei RYU ; Sunhwa PARK ; Jung Won CHUN ; Eunhae CHO ; Jongmun CHOI ; Dong-Eun LEE ; Hyoeun SHIM ; Yun-Hee KIM ; Sung-Sik HAN ; Sang-Jae PARK ; Sang Myung WOO ; Sun-Young KONG
Cancer Research and Treatment 2023;55(4):1303-1312
Purpose:
The genetic attribution for pancreatic ductal adenocarcinoma (PDAC) has been reported as 5%-10%. However, the incidence of germline pathogenic variants (PVs) in Korean PDAC patients has not been thoroughly investigated. Therefore, we studied to identify the risk factors and prevalence of PV for future treatment strategies in PDAC.
Materials and Methods:
Total of 300 (155 male) patients with a median age of 65 years (range, 33 to 90 years) were enrolled in National Cancer Center in Korea. Cancer predisposition genes, clinicopathologic characteristics, and family history of cancer were analyzed.
Results:
PVs were detected in 20 patients (6.7%, median age 65) in ATM (n=7, 31.8%), BRCA1 (n=3, 13.6%), BRCA2 (n=3), and RAD51D (n=3). Each one patient showed TP53, PALB2, PMS2, RAD50, MSH3, and SPINK1 PV. Among them, two likely PVs were in ATM and RAD51D, respectively. Family history of various types of cancer including pancreatic cancer (n=4) were found in 12 patients. Three patients with ATM PVs and a patient with three germline PVs (BRCA2, MSH3, and RAD51D) had first-degree relatives with pancreatic cancer. Familial pancreatic cancer history and PVs detection had a significant association (4/20, 20% vs. 16/264, 5.7%; p=0.035).
Conclusion
Our study demonstrated that germline PVs in ATM, BRCA1, BRCA2, and RAD51D are most frequent in Korean PDAC patients and it is comparable to those of different ethnic groups. Although this study did not show guidelines for germline predisposition gene testing in patients with PDAC in Korea, it would be emphasized the need for germline testing for all PDAC patients.
4.Modulation of Vascular Smooth Muscle Cell Phenotype by High Mobility Group AT-Hook 1
Yoojin JUNG ; Hae Sun LEE ; Jung Min HA ; Seo Yeon JIN ; Hye Jin KUM ; Farzaneh VAFAEINIK ; Hong Koo HA ; Sang Heon SONG ; Chi Dae KIM ; Sun Sik BAE
Journal of Lipid and Atherosclerosis 2021;10(1):99-110
Objective:
The purpose of this study is to examine the effect of high mobility group AT-hook 1 (HMGA1) on the phenotyptic change of vascular smooth muscle cells (VSMCs).
Methods:
Gene silencing and overexpression of HMGA1 were introduced to evaluate the effect of HMGA1 expression on the phenotypic change of VSMCs. Marker gene expression of VSMCs was measured by promoter assay, quantitative polymerase chain reaction, and western blot analysis. Common left carotid artery ligation model was used to establish in vivo neointima formation.
Results:
HMGA1 was expressed strongly in the synthetic type of VSMCs and significantly downregulated during the differentiation of VSMCs. Silencing of HMGA1 in the synthetic type of VSMCs enhanced the expression of contractile marker genes thereby enhanced angiotensin II (Ang II)-dependent contraction, however, significantly suppressed proliferation and migration. Stimulation of contractile VSMCs with platelet-derived growth factor (PDGF) enhanced HMGA1 expression concomitant with the downregulation of marker gene expression which was blocked significantly by the silencing of HMGA1. Silencing of HMGA1 retained the Ang II-dependent contractile function, which was curtailed by PDGF stimulation, however, overexpression of HMGA1 in the contractile type of VSMCs suppressed marker gene expression. Proliferation and migration were enhanced significantly by the overexpression of HMGA1. Furthermore, the Ang II-dependent contraction was reduced significantly by the overexpression of HMGA1. Finally, the expression of HMGA1 was enhanced significantly in the ligated artery, especially in the neointima area.
Conclusion
HMGA1 plays an essential role in the phenotypic modulation of VSMCs.Therefore, paracrine factors such as PDGF may affect vascular remodeling through the regulation of HMGA1.
5.Cataract Surgery Practices in the Republic of Korea: A Survey of the Korean Society of Cataract and Refractive Surgery 2018
Jin Kwon CHUNG ; Hyung Keun LEE ; Mee Kum KIM ; Hong Kyun KIM ; Sun Woong KIM ; Eun Chul KIM ; Hyun Seung KIM
Korean Journal of Ophthalmology 2019;33(5):451-457
PURPOSE: To describe current cataract surgery practice patterns and changing trends among Korean ophthalmologists. METHODS: A survey of members of the Korean Society of Cataract and Refractive Surgery was performed in July 2018. One hundred and two (12.7%) of 801 questionnaires were returned for analysis. The data were analyzed using descriptive statistics and compared with previous surveys. RESULTS: Most of the respondents (75%) had been in practice for 6 or more years and performed an average of 31 cataract surgeries per month. The preferred method for cataract surgery was phacoemulsification (95%); 5% used a femtosecond laser. The use of topical anesthesia markedly increased from 69% (2012) to 80% (2018). The use of optical biometry exceeded that of ultrasound A-scan biometry. A multifocal intraocular lens was used by 76% of the respondents compared with 44% of the respondents in 2012. Topical nonsteroidal anti-inflammatory drugs were used by 70% of the respondents postoperatively. Most (59%) of these anti-inflammatory drugs were prescribed for 4 weeks. CONCLUSIONS: This survey provided a comprehensive update of the present cataract surgery practices in the Republic of Korea. The results emphasized the increasing use of premium intraocular lenses, optical biometry, and topical anesthesia.
Anesthesia
;
Biometry
;
Cataract
;
Lenses, Intraocular
;
Methods
;
Phacoemulsification
;
Refractive Surgical Procedures
;
Republic of Korea
;
Surveys and Questionnaires
;
Ultrasonography
6.Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions.
Sun Hyun BAE ; Mi Sook KIM ; Won Il JANG ; Chul Koo CHO ; Hyung Jun YOO ; Kum Bae KIM ; Chul Ju HAN ; Su Cheol PARK ; Dong Han LEE
Journal of Korean Medical Science 2015;30(8):1055-1061
This study evaluated the incidence of hepatic toxicity after stereotactic ablative radiotherapy (SABR) using 3 fractions to the liver, and identified the predictors for hepatic toxicity. We retrospectively reviewed 78 patients with primary and metastatic liver cancers, who underwent SABR using 3 fractions between 2003 and 2011. To examine the incidence of hepatic toxicity, we defined newly developed hepatic toxicity> or =grade 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 within 3 months after the end of SABR as a significant adverse event. To identify the predictors for hepatic toxicity, we analyzed several clinical and dosimetric parameters (rV(5Gy)-rV(35Gy): normal liver volume receiving
Aged
;
*Dose Fractionation
;
Female
;
Hepatitis/*etiology/pathology/prevention & control
;
Humans
;
Liver Neoplasms/complications/pathology/*surgery
;
Male
;
Middle Aged
;
Neoplasm Metastasis
;
Radiation Injuries/*etiology/pathology/prevention & control
;
Radiosurgery/*adverse effects/*methods
;
Radiotherapy Dosage
;
Treatment Outcome
7.Feasibility and Efficacy of Stereotactic Ablative Radiotherapy for Barcelona Clinic Liver Cancer-C Stage Hepatocellular Carcinoma.
Sun Hyun BAE ; Mi Sook KIM ; Chul Koo CHO ; Kum Bae KIM ; Dong Han LEE ; Chul Ju HAN ; Su Cheol PARK ; Young Han KIM
Journal of Korean Medical Science 2013;28(2):213-219
The purpose of this study was to assess the feasibility and efficacy of stereotactic ablative radiotherapy (SABR) for liver tumor in patients with Barcelona Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma (HCC). We retrospectively reviewed the medical records of 35 patients between 2003 and 2011. Vascular invasion was diagnosed in 32 patients, extrahepatic metastases in 11 and both in 8. Thirty-two patients were categorized under Child-Pugh (CP) class A and 3 patients with CP class B. The median SABR dose was 45 Gy (range, 30-60 Gy) in 3-5 fractions. The median survival time was 14 months. The 1- and 3-yr overall survival (OS) rate was 52% and 21%, respectively. On univariate analysis, CP class A and biologically equivalent dose > or = 80 Gy10 were significant determinants of better OS. Severe toxicity above grade 3, requiring prompt therapeutic intervention, was observed in 5 patients. In conclusion, SABR for BCLC-C stage HCC showed 1-yr OS rate of 52% but treatment related toxicity was moderate. We suggest that patients with CP class A are the best candidate and at least SABR dose of 80 Gy10 is required for BCLC-C stage.
Adult
;
Aged
;
Carcinoma, Hepatocellular/mortality/*radiotherapy
;
Feasibility Studies
;
Female
;
Follow-Up Studies
;
Humans
;
Liver Failure/etiology
;
Liver Neoplasms/mortality/*radiotherapy
;
Male
;
Middle Aged
;
Myelitis/etiology
;
Neoplasm Staging
;
Prognosis
;
Radiation Dosage
;
Retrospective Studies
;
Severity of Illness Index
;
Stereotaxic Techniques
;
Survival Rate
8.Phosphodiesterase Inhibitor Improves Renal Tubulointerstitial Hypoxia of the Diabetic Rat Kidney.
Hui Kyoung SUN ; Yun Mi LEE ; Kum Hyun HAN ; Han Seong KIM ; Seon Ho AHN ; Sang Youb HAN
The Korean Journal of Internal Medicine 2012;27(2):163-170
BACKGROUND/AIMS: Renal hypoxia is involved in the pathogenesis of diabetic nephropathy. Pentoxifyllin (PTX), a nonselective phosphodiesterase inhibitor, is used to attenuate peripheral vascular diseases. To determine whether PTX can improve renal hypoxia, we investigated its effect in the streptozocin (STZ)-induced diabetic kidney. METHODS: PTX (40 mg/kg, PO) was administered to STZ-induced diabetic rats for 8 weeks. To determine tissue hypoxia, we examined hypoxic inducible factor-1alpha (HIF-1alpha), heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and glucose transporter-1 (GLUT-1) levels. We also tested the effect of PTX on HIF-1alpha in renal tubule cells. RESULTS: PTX reduced the increased protein creatinine ratio in diabetic rats at 8 weeks. HIF-1alpha, VEGF, and GLUT-1 mRNA expression increased significantly, and the expression of HO-1 also tended to increase in diabetic rats. PTX significantly decreased mRNA expression of HIF-1alpha and VEGF at 4 and 8 weeks, and decreased HO-1 and GLUT-1 at 4 weeks. The expression of HIF-1alpha protein was significantly increased at 4 and 8 weeks in tubules in the diabetic rat kidney. PTX tended to decrease HIF-1alpha protein expression at 8 weeks. To examine whether PTX had a direct effect on renal tubules, normal rat kidney cells were stimulated with CoCl2 (100 microM), which enhanced HIF-1alpha mRNA and protein levels under low glucose conditions (5.5 mM). Their expressions were similar even after high glucose (30 mM) treatment. PTX had no effect on HIF-1alpha expression. CONCLUSIONS: PTX attenuates tubular hypoxia in the diabetic kidney.
Animals
;
Anoxia/*drug therapy/enzymology/etiology/genetics
;
Cell Line
;
Cobalt/pharmacology
;
Diabetes Mellitus, Experimental/*complications
;
Diabetic Nephropathies/*drug therapy/enzymology/etiology/genetics
;
Disease Models, Animal
;
Gene Expression Regulation/drug effects
;
Glucose/metabolism
;
Glucose Transporter Type 1/genetics
;
Heme Oxygenase (Decyclizing)/genetics/metabolism
;
Hypoxia-Inducible Factor 1, alpha Subunit/genetics/metabolism
;
Kidney Tubules/*drug effects/enzymology
;
Male
;
Pentoxifylline/*pharmacology
;
Phosphodiesterase Inhibitors/*pharmacology
;
RNA, Messenger/metabolism
;
Rats
;
Rats, Sprague-Dawley
;
Streptozocin
;
Time Factors
;
Vascular Endothelial Growth Factor A/genetics
9.Effect on Glycemic, Blood Pressure, and Lipid Control according to Education Types.
Mi Ju CHOI ; Seung Hyun YOO ; Kum Rae KIM ; Yoo Mi BAE ; Sun Hee AHN ; Seong Shin KIM ; Seong Ah MIN ; Jin Sun CHOI ; Seung Eun LEE ; Yeo Jin MOON ; Eun Jung RHEE ; Cheol Young PARK ; Won Young LEE ; Ki Won OH ; Sung Woo PARK ; Sun Woo KIM
Diabetes & Metabolism Journal 2011;35(6):580-586
BACKGROUND: Diabetes self-management education and reinforcement are important for effective management of the disease. We investigated the effectiveness of interactive small-group education on glycemic, blood pressure, and lipid levels. METHODS: For this study, 207 type 2 diabetes patients with suboptimal glycemic control (HbA1c levels >6.5%) were enrolled. The conventional education group received an existing education program from April to November in 2006, and the interactive education group received a new small-group education program from December 2006 to July 2007. The two groups were comparatively analyzed for changes in blood sugar, glycated hemoglobin, lipid, and blood pressure at baseline, 3, 6, and 12 months and the proportion of patients achieving target goals at 12 months. RESULTS: After 12 months of follow-up, HbA1c levels in the interactive education group were significantly lower than in the conventional education group (6.7% vs. 6.4%, P<0.001). Fasting and 2 hour postprandial glucose concentrations, total cholesterol, and low density lipoprotein cholesterol were significantly lower in the interactive education group than in the conventional education group. The proportion of patients that achieved target goals was significantly higher in the interactive education group. CONCLUSION: The small-group educational method improved and re-established the existing group educational method. This finding suggests that the importance of education appears to be related to the method by which it is received rather than the education itself. Thus, the use of small-group educational methods to supplement existing educational methods established for diverse age levels should be considered in the future.
Achievement
;
Blood Glucose
;
Blood Pressure
;
Cholesterol
;
Cholesterol, LDL
;
Diabetes Mellitus
;
Fasting
;
Follow-Up Studies
;
Glucose
;
Hemoglobins
;
Humans
;
Lipoproteins
;
Reinforcement (Psychology)
;
Self Care
10.WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study.
Jin Man KIM ; Young Hyeh KO ; Seung Sook LEE ; Jooryung HUH ; Chang Suk KANG ; Chul Woo KIM ; Yun Kyung KANG ; Jai Hyang GO ; Min Kyung KIM ; Wan Seop KIM ; Yoon Jung KIM ; Hyun Jung KIM ; Hee Kyung KIM ; Jong Hee NAM ; Hyung Bae MOON ; Chan Kum PARK ; Tae In PARK ; Young Ha OH ; Dong Wha LEE ; Jong Sil LEE ; Juhie LEE ; Hyekyung LEE ; Sung Chul LIM ; Kyu Yun JANG ; Hee Kyung CHANG ; Yoon Kyung JEON ; Hye Ra JUNG ; Min Sun CHO ; Hee Jeong CHA ; Suk Jin CHOI ; Jae Ho HAN ; Sook Hee HONG ; Insun KIM
Korean Journal of Pathology 2011;45(3):254-260
BACKGROUND: The aim of study was to determine the relative frequency of malignant lymphoma according to World Health Organization (WHO) classification in Korea. METHODS: A total of 3,998 cases diagnosed at 31 institutes between 2005 and 2006 were enrolled. Information including age, gender, pathologic diagnosis, site of involvement and immunophenotypes were obtained. RESULTS: The relative frequency of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) was 95.4% and 4.6%, respectively. B-cell lymphomas accounted for 77.6% of all NHL, while T/natural killer (T/NK)-cell lymphomas accounted for 22.4%. The most frequent subtypes of NHL were diffuse large B-cell lymphoma (42.7%), extranodal marginal zone B-cell lymphoma (MZBCL) of mucosa-associated lymphoid tissue (19.0%), NK/T-cell lymphoma (6.3%) and peripheral T-cell lymphoma (PTCL), unspecified (6.3%), in decreasing order. The relative frequency of HL was nodular sclerosis (47.4%), mixed cellularity (30.6%), and nodular lymphocyte predominant (12.1%) subtypes. Compared with a previous study in 1998, increase in gastric MZBCL and nodular sclerosis HL, and slight decrease of follicular lymphoma, PTCL, and NK/T-cell lymphoma were observed. CONCLUSIONS: Korea had lower rates of HL and follicular lymphoma, and higher rates of extranodal NHL, extranodal MZBCL, and NK/T-cell lymphoma of nasal type compared with Western countries. Changes in the relative frequency of lymphoma subtypes are likely ascribed to refined diagnostic criteria and a change in national health care policy.
Academies and Institutes
;
Delivery of Health Care
;
Hodgkin Disease
;
Korea
;
Lymphocytes
;
Lymphoid Tissue
;
Lymphoma
;
Lymphoma, B-Cell
;
Lymphoma, B-Cell, Marginal Zone
;
Lymphoma, Follicular
;
Lymphoma, Non-Hodgkin
;
Lymphoma, T-Cell, Peripheral
;
Sclerosis
;
World Health Organization

Result Analysis
Print
Save
E-mail